Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714116 | 0.85 | KDM4E (0.54) | KDM4EHSD17B10ALDH1A1HDAC6 | |
| SCHEMBL17833376 | 0.81 | TSHR (0.50) | KDM4EMEN1ALDH1A1KMT2AHDAC6 | |
| SCHEMBL17833377 | 0.79 | L3MBTL1 (0.64) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL17824316 | 0.78 | CYP2C9 (0.48) | KDM4EALDH1A1 | |
| SCHEMBL3587930 | 0.74 | KDM4E (0.69) | PTGDR2KDM4EHSD17B10APEX1MEN1 | |
| SCHEMBL15643258 | 0.73 | APEX1 (0.71) | PTGDR2KDM4EHSD17B10APEX1MEN1 | |
| SCHEMBL5476584 | 0.72 | TSPO (0.62) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL31596375 | 0.72 | APEX1 (0.73) | PTGDR2KDM4EHSD17B10APEX1MEN1 | |
| SCHEMBL18955291 | 0.72 | APEX1 (0.73) | PTGDR2KDM4EHSD17B10APEX1MEN1 | |
| SCHEMBL19713871 | 0.71 | CYP1A2 (0.63) | PTGDR2KDM4EHSD17B10APEX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | HERIOT-WATT UNIVERSITY (GB) | 2017-12-21 | — | — | US | disclosed |
| EP-3230275-A1 | PRO-SURVIVAL COMPOUNDS | University Court of The University of Glasgow (GB) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092327-A1 | PRO-SURVIVAL COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | MCL1, MKI67, MORF4L1 | PTGDR2 2015/4885KDM4E 3457/4885HSD17B10 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.